Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded at Zacks Research

Zacks Research upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong sell rating to a hold rating in a research note published on Wednesday,Zacks reports.

A number of other analysts also recently weighed in on VNDA. B. Riley Financial reiterated a “buy” rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 31st. Oppenheimer started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Vanda Pharmaceuticals Stock Up 6.4%

VNDA stock opened at $3.82 on Wednesday. The company has a market cap of $231.00 million, a P/E ratio of -0.83 and a beta of 0.74. The company’s 50-day moving average price is $4.63 and its 200 day moving average price is $6.12. Vanda Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $9.94. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31. The business had revenue of $69.81 million for the quarter, compared to analysts’ expectations of $69.20 million. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. On average, research analysts expect that Vanda Pharmaceuticals will post -2.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at about $46,841,000. Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals in the second quarter worth about $1,354,000. State Street Corp grew its position in shares of Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after buying an additional 500,843 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Vanda Pharmaceuticals during the second quarter valued at $1,317,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter worth approximately $1,668,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.